Bespak in talks with potential acquirer:
This article was originally published in Clinica
UK drug delivery device manufacturer Bespak today revealed it is in "very preliminary" discussions with an unnamed party over a potential takeover bid for the company. The news gave a boost to the UK firm's shares, which have taken a tumble over recent months following disappointing sales of its Exubera insulin inhaler (see Clinica No 1265, p 13). Nomura Code analyst Charles Weston suggested that Bespak's potential suitors could include other medical device plastics manufacturer, who could generate significant cost synergies, or leveraged buy-out firms, who could use the company's strong free cash flow generation to "heavily gear the balance sheet".
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.